Scorecards: Quantifying Dosimetric Plan Quality in Pancreatic Ductal Adenocarcinoma Stereotactic Body Radiation Therapy

被引:2
|
作者
Rayn, Kareem [1 ,2 ]
Clark, Ryan [2 ]
Magliari, Anthony [2 ]
Jeffers, Brian [1 ]
Lavrova, Elizaveta [1 ]
Lozano, Ingrid Valencia [1 ]
Price, Michael J. [1 ]
Rosa, Lesley [2 ]
Horowitz, David P. [1 ]
机构
[1] Columbia Univ, Irving Med Ctr, Dept Radiat Oncol, New York, NY 10032 USA
[2] Varian Med Syst Inc, Palo Alto, CA 94304 USA
关键词
D O I
10.1016/j.adro.2023.101295
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: A scoring mechanism called the scorecard that objectively quantifies the dosimetric plan quality of pancreas stereotactic body radiation therapy treatment plans is introduced.Methods and Materials: A retrospective analysis of patients with pancreatic ductal adenocarcinoma receiving stereotactic body radiation therapy at our institution between November 2019 and November 2020 was performed. Ten patients were identified. All patients were treated to 36 Gy in 5 fractions, and organs at risk (OARs) were constrained based on Alliance A021501. The scorecard awarded points for OAR doses lower than those cited in Alliance A021501. A team of 3 treatment planners and 2 radiation oncologists, including a physician resident without plan optimization experience, discussed the relative importance of the goals of the treatment plan and added additional metrics for OARs and plan quality indexes to create a more rigorous scoring mechanism. The scorecard for this study consisted of 42 metrics, each with a unique piecewise linear scoring function which is summed to calculate the total score (maximum possible score of 365). The scorecard-guided plan, the planning and optimization for which were done exclusively by the physician resident with no prior plan optimization experience, was compared with the clinical plan, the planning and optimization for which were done by expert dosimetrists, using the Sign test.Results: Scorecard-guided plans had, on average, higher total scores than those clinically delivered for each patient, averaging 280.1 for plans clinically delivered and 311.7 for plans made using the scorecard (P = .003). Additionally, for most metrics, the average score of each metric across all 10 patients was higher for scorecard-guided plans than for clinically delivered plans. The scorecard guided the Conclusions: A scorecard tool can help clarify the goals of a treatment plan and provide an objective method for comparing the results of different plans. Our study suggests that a completely novice treatment planner can use a scorecard to create treatment plans with enhanced coverage, conformality, and improved OAR sparing, which may have significant effects on both tumor control and toxicity. These tools, including the scorecard used in this study, have been made freely available.& COPY; 2023 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Dosimetric Predictors of Local Control After Stereotactic Body Radiation Therapy of Locally Advanced Pancreatic Ductal Adenocarcinoma
    Chin, C.
    Perni, S.
    Yanagihara, T. K.
    Xanthopoulos, E. P.
    Yan, P.
    Horowitz, D. P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E215 - E216
  • [2] Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma
    Yanagihara, T.
    Jani, A.
    Oberstein, P. E.
    Chabot, J. A.
    Sherman, W. H.
    Schrope, B. A.
    Woo, Y.
    Hecht, E. M.
    Arindam, R.
    Chu, A.
    Salah, K.
    Addeo, D.
    Horowitz, D. P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E140 - E140
  • [3] Macrophage infiltration and polarization in pancreatic ductal adenocarcinoma following stereotactic body radiation therapy
    Marrero, Emil D. Gonzalez
    Wang, Liang
    Schrank, Benjamin R.
    Koong, Albert C.
    CANCER RESEARCH, 2024, 84 (06)
  • [4] Neoadjuvant stereotactic body radiation therapy for nonmetastatic pancreatic adenocarcinoma
    Jiang, Wei
    Haque, Waqar
    Verma, Vivek
    Butler, E. Brian
    Teh, Bin S.
    ACTA ONCOLOGICA, 2019, : 1259 - 1266
  • [5] Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma
    Simoni, N.
    Micera, R.
    Paiella, S.
    Guariglia, S.
    Zivelonghi, E.
    Malleo, G.
    Rossi, G.
    Addari, L.
    Giuliani, T.
    Pollini, T.
    Cavedon, C.
    Salvia, R.
    Milella, M.
    Bassi, C.
    Mazzarotto, R.
    CLINICAL ONCOLOGY, 2021, 33 (01) : E31 - E38
  • [6] Update of Stereotactic body radiation therapy for pancreatic adenocarcinoma: efficacy and safety
    Chen, X.
    Sanchez, E.
    Montero, A.
    Hernando, O.
    Lopez, M.
    Garcia, J.
    Perez, J. M.
    Ciervide, R.
    Valero, J.
    Garcia-Aranda, M.
    Alonso, R.
    Zucca, D.
    De la Casa, M. A.
    Alvarez, B.
    Marti, J.
    Alonso, L.
    Fernandez-Leton, P.
    Rubio, C.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S674 - S674
  • [7] Stereotactic body radiation therapy as neoadjuvant/radical treatment for pancreatic adenocarcinoma
    Zhao, X. Chen
    Sanchez Saugar, E.
    Lopez Gonzalez, M.
    Hernando Requejo, O.
    Montero Luis, A.
    Garcia Ruiz-Zorrilla, J.
    De la Casa de Julian, M.
    Garcia-Aranda Pez, M.
    Ciervide Jurio, R.
    Valero Albarran, J.
    Palma Delgado, J.
    Alonso Gutierrez, R.
    Perez Moreno, J.
    Alonso Iracheta, L.
    Zucca Aparicio, D.
    Garcia de Acilu, P.
    Marti Asenjo, J.
    Fernandez Leton, P.
    Rubio Rodriguez, C.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S777 - S777
  • [8] Neoadjuvant treatment of pancreatic adenocarcinoma: Chemoradiation or stereotactic body radiation therapy?
    Huguet, F.
    Cerbai, C.
    Ta, M. H.
    Sarrade, T.
    Evin, C.
    Aziez, S.
    del Campo, E. Rivin
    Durand, B.
    Loi, M.
    CANCER RADIOTHERAPIE, 2022, 26 (6-7): : 858 - 864
  • [9] Outcomes of pancreatic ductal adenocarcinoma (PDAC) patients treated with neoadjuvant stereotactic body radiation therapy (SBRT) or conventionally fractionated radiation therapy (CFRT).
    Zhu, Fan
    Wang, Haoyu
    Ashamalla, Hani
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Single Cell Sequencing of Pancreatic Ductal Adenocarcinoma Reveals a Paradoxical Immunosuppressive Microenvironment Following Stereotactic Body Radiation Therapy
    Bernard, V.
    Elhammali, A.
    Lin, D.
    Pant, S.
    Tzeng, C. W.
    Bhutani, M. S.
    Maitra, A.
    Navin, N.
    Taniguchi, C. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E189 - E190